395 related articles for article (PubMed ID: 24374152)
1. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
[TBL] [Abstract][Full Text] [Related]
2. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1131-6. PubMed ID: 24368175
[TBL] [Abstract][Full Text] [Related]
3. Exploratory drug safety: a discovery strategy to reduce attrition in development.
Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
[TBL] [Abstract][Full Text] [Related]
4. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
5. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
McGivern JV; Ebert AD
Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical Safety and Toxicology.
Stark C; Steger-Hartmann T
Handb Exp Pharmacol; 2016; 232():261-83. PubMed ID: 26489827
[TBL] [Abstract][Full Text] [Related]
7. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.
Chapman K; Chivers S; Gliddon D; Mitchell D; Robinson S; Sangster T; Sparrow S; Spooner N; Wilson A
Drug Discov Today; 2014 May; 19(5):528-32. PubMed ID: 24448068
[TBL] [Abstract][Full Text] [Related]
9. Computational toxicology--a tool for early safety evaluation.
Merlot C
Drug Discov Today; 2010 Jan; 15(1-2):16-22. PubMed ID: 19835978
[TBL] [Abstract][Full Text] [Related]
10. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
Giri S; Bader A
Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
[TBL] [Abstract][Full Text] [Related]
11. Toxicology Strategies for Drug Discovery: Present and Future.
Blomme EA; Will Y
Chem Res Toxicol; 2016 Apr; 29(4):473-504. PubMed ID: 26588328
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from candidate drug attrition.
Empfield JR; Leeson PD
IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
[TBL] [Abstract][Full Text] [Related]
13. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
14. Drug discovery through stem cell-based organoid models.
Ranga A; Gjorevski N; Lutolf MP
Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
[TBL] [Abstract][Full Text] [Related]
15. The application of 3D cell models to support drug safety assessment: opportunities & challenges.
Roth A; Singer T
Adv Drug Deliv Rev; 2014 Apr; 69-70():179-89. PubMed ID: 24378580
[TBL] [Abstract][Full Text] [Related]
16. Challenges of antibacterial discovery revisited.
Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
[TBL] [Abstract][Full Text] [Related]
17. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
Campbell JB
IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
[TBL] [Abstract][Full Text] [Related]
18. Addressing toxicity risk when designing and selecting compounds in early drug discovery.
Segall MD; Barber C
Drug Discov Today; 2014 May; 19(5):688-93. PubMed ID: 24451294
[TBL] [Abstract][Full Text] [Related]
19. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
[TBL] [Abstract][Full Text] [Related]
20. Toxicology in the drug discovery and development process.
Dorato MA; Buckley LA
Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
